全文获取类型
收费全文 | 1897篇 |
免费 | 104篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 123篇 |
妇产科学 | 37篇 |
基础医学 | 198篇 |
口腔科学 | 42篇 |
临床医学 | 237篇 |
内科学 | 380篇 |
皮肤病学 | 24篇 |
神经病学 | 101篇 |
特种医学 | 276篇 |
外科学 | 189篇 |
综合类 | 29篇 |
一般理论 | 1篇 |
预防医学 | 104篇 |
眼科学 | 23篇 |
药学 | 156篇 |
中国医学 | 13篇 |
肿瘤学 | 60篇 |
出版年
2023年 | 13篇 |
2022年 | 8篇 |
2021年 | 16篇 |
2020年 | 15篇 |
2019年 | 20篇 |
2018年 | 45篇 |
2017年 | 29篇 |
2016年 | 34篇 |
2015年 | 41篇 |
2014年 | 49篇 |
2013年 | 59篇 |
2012年 | 84篇 |
2011年 | 91篇 |
2010年 | 71篇 |
2009年 | 71篇 |
2008年 | 70篇 |
2007年 | 57篇 |
2006年 | 46篇 |
2005年 | 58篇 |
2004年 | 54篇 |
2003年 | 50篇 |
2002年 | 55篇 |
2001年 | 49篇 |
2000年 | 55篇 |
1999年 | 40篇 |
1998年 | 55篇 |
1997年 | 59篇 |
1996年 | 74篇 |
1995年 | 51篇 |
1994年 | 49篇 |
1993年 | 52篇 |
1992年 | 34篇 |
1991年 | 34篇 |
1990年 | 24篇 |
1989年 | 49篇 |
1988年 | 46篇 |
1987年 | 42篇 |
1986年 | 40篇 |
1985年 | 34篇 |
1984年 | 28篇 |
1983年 | 20篇 |
1982年 | 26篇 |
1981年 | 18篇 |
1980年 | 9篇 |
1979年 | 5篇 |
1978年 | 11篇 |
1977年 | 15篇 |
1976年 | 15篇 |
1975年 | 15篇 |
1968年 | 6篇 |
排序方式: 共有2011条查询结果,搜索用时 15 毫秒
1.
2.
Bryan E.K. Guevara Suhail Saleem Wan‐Ting Chen Pa‐Fan Hsiao Yu‐Hung Wu 《Journal of cutaneous pathology》2019,46(5):347-352
Lucio phenomenon is an atypical reaction of leprosy, characterized by vasculitic lesions that can mimic antiphospholipid syndrome (APS) clinically. Distinguishing the two can be difficult as antiphospholipid autoantibodies may be present in patients with leprosy. We report on a 32‐year‐old female patient presenting with a sudden onset of fever, hemorrhagic bullae, and skin necrosis on her lower legs. She was treated for APS due to the presence of antiphospholipid antibodies but had an inadequate response. A skin biopsy revealed thrombotic vasculopathy and necrotizing vasculitis associated with aggregation of foam cells in the perivascular area and subcutis, with acid‐fast bacilli in the histiocytes and blood vessel walls. Direct immunofluorescence showed IgM, C3, and fibrinogen deposition in the superficial and deep dermal blood vessels. The pathology confirmed the diagnosis of Lucio phenomenon, and appropriate therapy was given. It is essential to evaluate the patient comprehensively, including clinical, serological, and pathological aspects, to obtain the correct diagnosis. 相似文献
3.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
4.
J Doniec K Folta T Ga?dzik M Pa?ciak 《Chirurgia narzadów ruchu i ortopedia polska》1990,55(4-6):501-506
The principles of treatment of tibial pseudoarthroses complicated by skin and soft tissue loss with the use of cancellous bone grafts from posterolateral approach to the tibia by Harmon method were discussed. The detailed surgical technique was presented. Management of 3 patients that resulted in bone union was described. 相似文献
5.
6.
7.
8.
J Sabán J L Rodríguez-García J Gil J R País S Medina 《The Netherlands journal of medicine》1991,39(5-6):350-352
The aetiology of porphyria cutanea tarda (PCT) has not been elucidated, but the possibility of an autoimmune mechanism has been proposed. We report a case of an unknown clinical combination of PCT with autoimmune hypothyroidism, alopecia universalis and vitiligo with thyroid and parietal cell circulating antibodies. This is highly suggestive of underlying autoimmune damage in this patient. 相似文献
9.
10.